UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 5, 2006
Tapestry Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
| 0-24320 |
| 84-1187753 |
(State of |
| (Commission |
| IRS Employer |
incorporation) |
| File Number) |
| Identification No.) |
4840 Pearl East Circle, Suite 300W
Boulder, Colorado 80301
(Address of principal executive offices and zip code)
(303) 516-8500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
Bonus Payments
On October 5, 2006, the Compensation Committee of the Board of Directors of the Company approved the payment in January 2007 of the following cash bonuses to executive officers of the Company. No changes were made to the salaries of such officers.
Executive Officer |
| Position |
| Bonus |
| |
Leonard Shaykin |
| Chairman and Chief Executive Officer |
| $ | 250,000 |
|
Martin Batt |
| Chief Operating Officer |
| $ | 100,000 |
|
Gordon Link |
| Chief Financial Officer |
| $ | 100,000 |
|
Kai Larson |
| Vice President and General Counsel |
| $ | 75,000 |
|
2
SIGNATURES
According to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Date: October 12, 2006 |
| TAPESTRY PHARMACEUTICALS, INC. | ||
|
|
|
|
|
|
| By: |
| /s/ Kai Larson |
|
| Name: |
| Kai Larson |
|
| Title: |
| Vice President, General Counsel |
3